nefazodone
Sign in to saveAlso known as BMY-13754, MJ-13754-1, 1-{3-[4-(m-chlorophenyl)-1-piperazinyl]propyl}-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one
composto chimico
Research
829 papers- Nefazodone.2012
- Nefazodone: a new antidepressant.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 1995
- Nefazodone: its place among antidepressants.The Annals of pharmacotherapy · 1996
- Clinical pharmacokinetics of nefazodone.Clinical pharmacokinetics · 1997
- Nefazodone-induced mania.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 1995
via PubMed
Wikidata facts
- Mass
- 469.224
Show 5 more facts
- chemical formula
- C₂₅H₃₂ClN₅O₂
- canonical SMILES
- CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
- World Health Organisation international non-proprietary name
- nefazodone
- defined daily dose
- 0.4
- Commons category
- Nefazodone
Sources (6)
via Wikidata · CC0
Article · Italiano
Nefazodone è una molecola con attività antidepressiva. Il farmaco può essere usato nel trattamento del disturbo depressivo maggiore, disturbo distimico, e nella fase depressiva del disturbo bipolare. Come molti altri antidepressivi, il trattamento può richiedere diverse settimane prima di determinare effetti benefici.In Italia il farmaco non è più commercializzato.
Abstract from DBpedia / Wikipedia · CC BY-SA
Connections
propranolol
Entity
adrenergic receptor
Entity
N-methylserotonin
Entity
antidepressant
Entity
pharmacokinetics
Entity
histamine antagonist
Entity
biological half-life
Entity
atenolol
Entity
monoamine oxidase inhibitor
Entity
tricyclic antidepressant
Entity
labetalol
Entity
serotonin–norepinephrine reuptake inhibitor
Entity
ergoline
Entity
liver disease
Entity
(Z)-thiothixene
Entity
DRD2
Gene
Histamine receptor H1
Protein
levobunolol
Entity
tetracyclic antidepressant
Entity
glaucine
Entity
Categories
1,2,4-Triazol-3-ones1-Phenylpiperazines3-Chlorophenyl compounds5-HT1A agonists5-HT2A antagonists5-HT2C antagonistsAlpha-1 blockersAlpha-2 blockersAntidepressantsAnxiolyticsCYP3A4 inhibitorsDrugs with non-standard legal statusH1 receptor antagonistsHepatotoxinsPhenol ethersSerotonin–norepinephrine–dopamine reuptake inhibitorsUreasWithdrawn drugs